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Background: Symptomatic primary HIV infection is associated with an adverse prognosis, and immediate initiation
of combination antiretroviral therapy (cART) is recommended. However, little is known about immunological
predictors of immune recovery. Thymic Stromal Lymphopoietin (TSLP) is a cytokine that promotes CD4+ T cells
homeostatic polyclonal proliferation and regulates Th17/regulatory T-cell balance, immunological functions known
to be affected during primary HIV infection. The aim of this study was to describe immune recovery in primary and
chronic HIV infection and possible impact of TSLP.
Methods: Prospective study including 100 HIV-infected individuals (primary HIV infection (N = 14), early presenters
(>350 CD4+ T cells/μL, N = 42), late presenters without advanced disease (200–350 CD4+ T cells/μL, N = 24) and
with advanced disease (<200 CD4+ T cells/μL, N = 20) and). Immune recovery was defined as increase in CD4+ T
cells count from baseline to a given time of follow-up. Plasma TSLP was determined using ELISA and CD4+ T cell
subpopulations (recent thymic emigrants, naïve and memory cells) were measured using flow cytometry at baseline
and after 6, 12 and 24 months of cART.
Results: Immune recovery was comparable in all groups, and no differences in immune homeostasis were found
between primary HIV infection and early presenters, whereas differences in absolute counts and proportions of CD4+ T
cell subpopulations were found between primary HIV infection and late presenters. TSLP was elevated in primary HIV
infection at baseline and after 24 months of cART. Interestingly, TSLP was negatively associated with proportion of
recent thymic emigrants (correlation coefficient −0.60, p = 0.030). TSLP was not associated with immune recovery in
primary HIV infection.
Conclusions: Immune recovery was comparable in primary and chronic HIV infection whereas differences in absolute
counts and proportions of CD4+ T cell subpopulations were found between primary HIV infection and late presenters
supporting early initiation of cART. Higher plasma TSLP was found in primary HIV infection, and TSLP was associated
with lower thymic output, but not with immune recovery. These findings indicate a possible role of TSLP in immune
homeostasis in HIV infection but do not support TSLP to affect immune recovery in primary HIV infection.
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WHO estimates that there are two million new cases of
HIV infection each year. It is estimated that 40-90 % of
newly infected individuals have symptomatic acute pri-
mary HIV infection, a mononucleosis-like syndrome that
appears right after the infection [1–3]. An association be-
tween symptomatic acute primary infection and a worse
prognosis in terms of decline in CD4+ T cells count and
progression to AIDS has been described [4–6]. Initiation
of combination antiretroviral therapy (cART) during the
primary HIV infection has been shown to result in faster
recovery of CD4+ T cells when compared to initiation of
cART during chronic phase of infection [7–9]. Note-
worthy, HIV-infected individuals that maintain a CD4+ T
cell count above 500 cells/μL have been shown to have
lower risk of both AIDS and all cause mortality [10]. Fur-
thermore, beneficial effect of early cART on both chronic
immune activation and viral reservoir has been
described [11, 12]. However, little is known about the
immunological predictors of immune recovery in indi-
viduals with primary HIV infection, and only few
studies have addressed T cell subsets distribution in
primary and chronic HIV infection [13, 14].
Our group has recently shown that Interleukin-7 (IL-7)
and IL-7 receptor (IL-7R) plasma concentrations are lower
in chronic untreated HIV infection, especially in those in-
dividuals with a low CD4+ T cell counts. Interestingly,
previous studies have demonstrated both high plasma IL-
7 and low T cell expression of IL-7R to be associated with
suboptimal CD4+ T cell recovery [15–19]. Furthermore, a
high IL-7 induced T cell response has been shown to be
associated with higher CD4+ T cell counts [20] suggesting
an important role for IL-7 and IL-7R in CD4+ T cell re-
covery in HIV infection. Thymic Stromal Lymphopoietin
(TSLP) and IL-7 are closely related cytokines both with a
prominent role in CD4+ T cell homeostasis [21]. TSLP is
produced by epithelial cells in skin, lung, gut, and thymus
and the TSLP receptor (TSLPR), a heterodimer composed
of CD127 and cytokine receptor-like factor 2 (CRLF2), is
widely distributed on CD4+ T cells and dendritic cells
(DC) reflecting a wide range of actions [22]. TSLP has
mainly been linked to priming of naïve CD4+ T cell to-
wards a Th2 response [23]. Interestingly, TSLP educated
DC have been shown to have an important role in the
homeostatic polyclonal expansion of naïve CD4+ T cells
[24]. Even more interesting, TSLP produced by the
Hassal’s corpuscles in the thymic medulla has been shown
to affect thymic output of CD4+ T cell in healthy HIV-
negative individuals [25]. However, the impact of TSLP on
T cell subset distribution during primary and chronic HIV
infection has not previously been reported.
This study was conducted to describe immune recovery
in primary and chronic HIV infection. Furthermore, we
aimed to determine circulating TSLP in primary andchronic HIV infection and the impact of TSLP on
immune recovery. We hypothesized that immunological
impairment would be less pronounced and immune re-
covery faster in individuals with primary HIV infection
compared to individuals with chronic infection with a
comparable baseline CD4+ T cell count. Finally, we hy-
pothesized that TSLP would be associated with immune
recovery. Thus, total CD4+ T cell counts as well as
proportions and absolute numbers of recent thymic emi-
grants (RTE), naïve and memory CD4 +T cells as well as
plasma concentrations of TSLP were measured in a total
of 100 individuals with either primary or chronic HIV in-




Plasma samples were obtained from 100 treatment naïve
HIV-infected individuals as previously described [26]. In-
clusion criteria were a positive HIV-1 test and initiation
of cART. Decision about cART initiation was made by
the patient’s physician and the patient, and participation
in this study did not influence this decision. All individ-
uals were enrolled from Department of Infectious Dis-
eases, Rigshospitalet, Copenhagen University Hospital or
Department of Infectious Diseases, Hvidovre Hospital. A
total of 14 participants were defined as having primary
HIV infection (PHI), i.e. they had a negative HIV test
less than 6 months prior to diagnosis and/or one or
more negative bands in Immune Blot. Fiebig stages for
patients with PHI are shown in Table 1. Participants
with chronic HIV infection were further divided in three
subgroups, according to CD4+ T cell count at baseline:
Late presenters with advanced disease (LP-AD, <200
CD4+ T cells/μL at presentation, N = 20), late presenters
without advanced disease (LP-nonAD, 200–350 CD4+ T
cells/μL at presentation; N = 24), and early presenters
(EP, >350 CD4+ T cells/μL at presentation, N = 42). The
majority of study participants were males (90.7 %), and
the median age was 39.1 years (IQR: 31.4-45.2). Blood
samples from 18 HIV-negative individuals were obtained
as controls (Table 1). No differences in sex and age
distribution were found between the groups.
Data comparing proportion of CD4+ T cell subsets in
the different groups of chronic HIV infection and
healthy controls is presented in another manuscript [26].
Therefore, in the present manuscript only comparisons
between PHI and the different groups of chronic HIV
infection and healthy controls are made.
Collection of blood samples and flow cytometry
Blood samples from HIV-infected participants were col-
lected at the day of inclusion (baseline/day 0 of cART)
and after 6, 12 and 24 months of cART. Blood samples
Table 1 Clinical characteristics of the study population
PHI LP-AD <200 cells/μL LP-nonAD 200–350 cells/μL EP >350 cells/μL HC
N = 14 N = 20 N = 24 N = 42 N = 18
Gender, males/females, (% males) 13/1 (92.9) 18/2 (90.0) 21/3 (87.5) 39/3 (92.9) 17/1 (94.4)
Age, years, median (IQR) 47 (12) 42 (16) 38 (16) 44.5 (12) 42.5 (12)
Time since diagnosis, days, median (IQR) 2 (3) 3 (9) 18 (269) 24 (983) NA
CD4+ nadir, cells/μL, median (IQR) 540 (335) 45 (113) 290 (95) 480 (170) NA
CD4+ at baseline, cells/μL, median (IQR) 550 (327) 55 (110) 290 (97) 510 (172) 983 (540)
CD4/CD8 at baseline, median (IQR) 0.5 (0.3) 0.1 (0.1) 0.3 (0.1) 0.5 (0.3) 1.5 (0.9)
Co-infection with chronic HBV/HCV, N 0/1 0/2 0/0 1/1 0/0
HIV-RNA at baseline, median (IQR) 151,775 (3,442,296) 196,589 (751,023) 65,990 (89,637) 49,422 (47,031) NA
AIDS defining events, N 0 1 0 0 NA
Fiebig Stage I, N 1 NA NA NA NA
Fiebig Stage II, N 1 NA NA NA NA
Fiebig Stage III, N 1 NA NA NA NA
Fiebig Stage IV, N 11 NA NA NA NA
Abbreviations: LP-AD late presenters with advanced disease, LP-nonAD late presenters without advanced disease, EP early presenters, PHI primary HIV infection, HC
healthy controls, NA not applicable
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time of inclusion. The numbers of samples available at
each timepoint (baseline, 6, 12 and 24 months after
initiation of cART) were: PHI: 14, 11, 8, 6; LP-AD: 20,
11, 11, 9; LP-nonAD: 24, 12, 14, 8; EP: 42, 24, 20, 10.
Blood collected in ethylenediamine tetraacetic acid
(EDTA) tubes was used for flow cytometry as described
previously [26]. In brief, 100 μL of EDTA blood was in-
cubated with fluorescent dye–conjugated monoclonal
antibodies, erythrocytes were lysed with 2 mL of Lysing
Solution (Becton Dickinson (BD), Franklin Lakes, NJ,
USA) and the samples were washed and resuspended in
Facs flow (BD). CD3 was used in combination with
CD4 to identify recent thymic emigrants (RTE, CD45RA
+ CD31+), naive cells (CD45RA + CD27 + CCR7+),
central memory (CM, CD45RA-CD27 + CCR7+), ef-
fector memory (EM, CD45RA-CD27 + CCR7-), and late
differentiated CD4+ T cells (LD, CD45RA+, CD27-,
CCR7-). Monoclonal antibodies used to determine lympho-
cyte subsets were CD8- PE-Cy7-A, CD3-fluorescein
isothiocyanate, CCR7-Phycoerythrin (PE), CD31-FITC,
CD45RA-APC, CD27-PE-Cy7 and CD4-APC-Cy7-A, and
appropriate isotype controls all purchased from BD. Ac-
quisition was performed using a FACS Canto, and data
were processed using FACS Diva software (BD). For each
sample a minimum of 100,000 cells were acquired and
gated as previously described by our group [27]. Represen-
tative plots and gating strategy is shown in Fig. 1.
TSLP determination by enzyme linked Immunosorbent assay
The concentration of TSLP was determined in snap
frozen plasma separated within 30 min after collection
and immediately stored at −80 °C. ELISA kit (eBioscience,San Diego, CA, USA) was used according to manufac-
turer’s instructions. Plasma concentration of TSLP was de-
termined in HIV-infected individuals with available
plasma samples at baseline (n = 90), 6 months after initi-
ation of cART (n = 57), 12 months after initiation of cART
(n = 53), and 24 months after initiation of cART (n = 33).
Plasma concentration of TSLP was determined in all
healthy controls (n = 18).
Statistical analysis
Differences between the groups of HIV-infected individ-
uals were evaluated by Kruskal-Wallis test and if signifi-
cant followed by Mann-Whitney U test. The effect of
baseline measures of TSLP on immune recovery and
changes in CD4 + T cell subsets distribution after initiating
cART were evaluated by Spearman test. Immune recovery
was defined as increase in CD4+ T cells count from base-
line to a given time of follow-up. When exploring correla-
tions between TSLP and CD4+ T cell subpopulations,
data from patients in each group were analyzed separately.
Two-tailed P-values <0.05 were considered significant. All
statistical analyses were performed using SPSS (version 22
- IBM corp., Armonk, New York, USA).
Results
CD4+ T cell count and CD4+ T cell subsets before and
after initiation of cART
Clinical characteristics of the study population are
shown in Table 1.
The CD4+ T cell count was comparable in PHI and EP
at all time points (Table 2). In contrast, differences in CD4+
T count between PHI and LP-AD and LP-nonAD were
found at baseline (Table 2). These differences remained 6
Fig. 1 Gating strategy for CD4+ T cells subpopulations. Gating of CD4+ RTE (CD4 + CD45RA + CD31+) (a) Gating of naive CD4+ T cells (CD45RA
+ CD27 + CCR7+), central memory CD4+ T cells (CM, CD45RA-CD27 + CCR7+), late differentiated CD4+ T cells (LD, CD45RA + CD27-CCR7-), and
effector memory CD4+ T cells (EM, CD45RA-CD27 + CCR7-) (b, c)
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tween PHI and LP-AD was also found after 24 months of
cART (Table 2). No differences in CD4+ T cell recovery
between PHI and any of the groups with chronic infec-
tions at any of the follow-up time points were found.
RTE and naïve CD4+ T cells were determined as
markers of thymic output, while EM, CM and LD were
determined to characterize the memory CD4+ T cell
subsets. No differences in proportion of these subsets
were found between PHI and EP at any timepoint. In
contrast, compared to LP-nonAD, PHI had lower pro-
portion of RTE after 6 and 24 months of cART and
lower proportion of naïve CD4+ T cells after 24 months
of cART (Table 2). No differences in effector memory
CD4+ T cells were found at any timepoint. However,
PHI had higher proportion of late differentiated CD4+ T
cells before and after 6 and 24 months of cART (Table 2).
When comparing PHI and LP-AD no differences in
proportion of RTE were found, while PHI had higher
proportion of naïve CD4+ T cell at baseline (Table 2).
Furthermore, PHI had lower proportions of effector
memory CD4+ T cells compared to LP-AD 6, 12 and
24 months after initiation of cART. Finally, PHI had
higher proportion of late differentiated CD4+ T cell after
24 months of cART compared to LP-AD (Table 2).
When comparing absolute cell counts, no differences in
RTE, naïve, CM, EM or LD cell counts were found between
PHI and EP at any timepoint (Fig. 2a-e). When comparing
PHI and LP-nonAD RTE cell count was lower in PHI after
24 months of cART (Fig. 2a). In contrast, the baseline naïve
cell count was higher in PHI than in LP-nonAD (Fig. 2b).Both CM and LD cell counts were higher in PHI compared
to LP-nonAD at baseline and after 6 months of cART
(Fig. 2c and d). When comparing PHI and LP-AD, the RTE
cell count was higher in PHI at baseline, and 6 and
24 months after the initiation of cART. Furthermore, PHI
had higher naïve and LD cell counts compared to LP-AD
before cART, and after 6 and 24 months. Finally, EM and
CM cell counts were higher in PHI than in LP-AD at base-
line and after 6 months of cART (Fig. 2c and e), and CM
cell count remained higher in PHI after 12 and 24 months.
CD4+ T cell subsets in patients with primary HIV infection
before and after initiation of cART versus healthy controls
The proportion of late differentiated CD4+ T cell was
higher in PHI than in HC at baseline and after 6 and
24 months of cART, while PHI had lower proportion of
RTE than HC after 12 months of cART. No differences in
proportion of naïve, effector memory and central memory
CD4+ T cell between PHI and HC were found (data not
shown). At baseline, PHI had lower absolute count of
RTE, naïve and central memory CD4+ T cells than HC
(Fig. 2a, b, c). Furthermore, PHI had lower effector mem-
ory absolute count compared to healthy controls after
6 months of cART (Fig. 2e), while the absolute count of
late differentiated CD4+ T cells was higher in PHI than in
HC both at 6 and 12 months of follow-up (Fig. 2d).
TSLP and IL-7 in plasma
Plasma concentrations of TSLP were determined at
baseline and after 6, 12 and 24 months of cART (Fig. 2f ).
Prior to initiation of cART, concentration of TSLP was
Table 2 CD4+ T cell subsets proportion in primary HIV infection before and after initiation of cART
Primary HIV (PHI) Chronic patients CD4 < 200 (LP-AD) Chronic patients CD4 200–350 (LP-nonAD) Chronic patients CD4 > 350 (EP) P*
N = 14 N = 20 N = 24 N = 42
Cells/μL CD4
Baseline 550 (327)a,b 55.5 (110)a 290 (97)b 510 (172) < .001
After 6 months of cART 740 (375)a,b 210 (280)a 450 (190)b 690 (265) < .001
After 12 months of cART 720 (435)a,b 340 (170)a 505 (198)b 740 (210) < .001
After 24 months of cART 680 (240)a 269 (160)a 695 (290) 820 (317) < .001
% CD4 Cells RTE
Baseline 14 (11) 11 (16) 20 (15) 18 (14) .063
After 6 months of cART 16 (11)b 8 (18) 27 (15)b 19 (15) .006
After 12 months of cART 8 (17) 6 (20) 17 (25) 5 (25) .588
After 24 months of cART 18 (9)b 17 (10) 28 (11)b 17 (16) .009
Naive
Baseline 43 (20)a 23 (30)a 40 (26) 44 (21) < .001
After 6 months of cART 37 (23) 22 (31) 49 (19) 39 (20) .031
After 12 months of cART 46 (30) 28 (28) 49 (19) 45 (24) .066
After 24 months of cART 36 (12)b 30 (16) 55 (16)b 37 (15) .002
EM
Baseline 12 (7) 17 (14) 16 (12) 12 (6) .009
After 6 months of cART 7 (4)a 18 (11)a 6 (4) 7 (4) .001
After 12 months of cART 9 (6)a 15 (14)a 7 (5) 6 (3) .007
After 24 months of cART 9 (4)a 15 (6)a 6 (7) 7 (5) .043
CM
Baseline 26 (6) 20 (22) 24 (10) 24 (10) .597
After 6 months of cART 29 (11) 35 (18) 27 (15) 28 (14) .969
After 12 months of cART 26 (8) 24 (16) 24 (11) 25 (10) .949
After 24 months of cART 24 (14) 30 (23) 24 (8) 32 (16) .784
LD
Baseline 5 (4)b 3 (12) 1 (2)b 5 (8) .009
After 6 months of cART 8 (11)b 3 (8) 1 (3)b 5 (7) .012
After 12 months of cART 7 (14) 4 (11) 2 (3) 7 (12) .126
After 24 months of cART 9 (16)a,b 1 (1)a 3 (2)b 9 (13) .038
Data are presented as median and (IQR)
Abbreviations: LP-AD late presenters with advanced disease, LP-nonAD late presenters without advanced disease, EP early presenters, PHI primary HIV infection
P*: comparing the four HIV groups by using Kruskal-Wallis test. If significant (<0.05) then Mann-Whitney was used to compare PHI group with the other chronic groups. Only significant differences are marked: aPHI vs
LP-AD; bPHI vs LP-nonAD; cPHI vs EP













Fig. 2 CD+ T cell subset prior to cART and during 24 months of follow up. Absolute counts of recent thymic emigrants (a), naïve (b), central memory (c),
late differentiated (d) and effector memory (e) CD4+ T cells. Plasma concentration of TSLP (f). The numbers of samples available at each timepoint
(baseline, 6, 12 and 24 months after initiation of cART) were PHI: 14, 11, 8, 6; LP-AD: 20, 11, 11, 9; LP-nonAD: 24, 12, 14, 8; EP: 42, 24, 20, 10. Mann-Whitney
was used to compare PHI group with the other chronic groups and healthy controls. Significant differences are marked: a: PHI vs. late presenters with
advanced disease; b: PHI vs. late presenters without advanced disease; c: PHI vs. early presenters; d: PHI vs. healthy controls
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groups of individuals with chronic infections (LP-AD,
LP-nonAD and EP). This difference was also found be-
tween PHI and both LP-AD and EP after 24 months ofcART (Fig. 2f ). IL-7 was previously measured in this
cohort [26]. Significant associations were not found
between IL-7 and TSLP concentrations in any of the
HIV-infected groups at any time points.
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subsets at baseline
To determine possible impact of TSLP on CD4+ T cell
recovery, associations between TSLP at baseline and
CD4+ T cell recovery at all time points after initiation of
cART were investigated. Higher plasma TSLP was
associated with lower CD4+ T cell recovery at 12 months
in the LP-nonAD group (correlation coefficient −0.50, P =
0.034). No other associations between TSLP and CD4+ T
cell recovery were found. Furthermore, the time period
from initiation of cART to a CD4+ T cells count ≥ 500
cells/μL was analyzed for all participants, and significant
correlation between this time period and plasma TSLP
was not found in any of the HIV-infected groups (data not
shown).
In addition, possible associations between TSLP at base-
line and proportion of CD4+ T cell subsets at baseline
were investigated. In PHI, plasma TSLP at baseline was
negatively associated with proportion of RTE (correlation
coefficient −0.60, P = 0.030). Furthermore, TSLP at base-
line was associated with a higher proportion of effector
memory cells in the EP group (correlation coefficient 0.33,
P = 0.048). No other significant associations were found.
Discussion
HIV-infected individuals presenting for care with pri-
mary HIV infection are offered immediate initiation of
cART, but information about immune homeostasis in
this group of individuals and possible predictors of CD4+
T cell recovery is incomplete. Both TSLP and IL-7 are
cytokines with important roles in regulation of CD4+ T
cell homeostasis. We and others have found plasma
Interleukin-7 and Interleukin-7R to impact CD4+ T cell
recovery after initiation of cART [19, 26]. In contrast,
little is known about potential roles of TSLP in HIV in-
fection. To study immune recovery and impact of TSLP
in both primary and chronic HIV infection a prospective
study of 100 individuals that initiated cART and were
followed up for two years was conducted. Individuals
with primary HIV infection and early presenters pre-
sented for care with comparable CD4+ T cell counts,
and immune homeostasis and CD4+ T cell recovery in
these two groups were similar. Interestingly, higher
plasma TSLP was found in PHI, compared to both
chronic HIV infection and healthy controls, and TSLP
was associated with lower proportion of RTE in PHI.
However, TSLP was not associated with CD4 + T cell re-
covery in this group. In contrast, TSLP was associated
with lower immune recovery in LP-nonAD.
Primary and chronic HIV infection is characterized by
differences in CD4+ T cell homeostasis [13, 28, 29].
However, to our knowledge, this is the largest prospect-
ive study to describe both thymic output (naïve and re-
cent thymic emigrants) and memory cells (central andeffector memory) in both acute and chronic HIV-
infected individuals. Naïve CD4+ T cells are one of the
first CD4+ T cell subpopulations to be infected during
primary HIV infection [13]. This causes a rapid decline
in CD4+ T cells which continues at a slower rate in
untreated individuals during the chronic phase of HIV
infection [13]. Accordingly, a higher proportion of naïve
CD4+ T cells was found in PHI compared to LP-AD be-
fore the initiation of cART. Furthermore, the proportion
of effector memory CD4+ T-cell is known to gradually
increase during HIV infection [30, 31]. In line with these
previous findings, we found lower proportion of CD4+
effector memory cells in PHI compared to LP-AD at 6,
12 and 24 months after the initiation of cART. In con-
trast, differences in subsets of CD4+ T cells or in CD4+
T cell immune recovery were not found when comparing
PHI and early presenters that had comparable CD4+ T cell
counts at baseline. Our findings suggest a beneficial effect
of early initiation of cART on both proportion of naïve
and effector memory CD4+ T cells. However, individuals
with primary HIV infections and early presenters initiating
cART early seem to have comparable T cell subsets distri-
bution at baseline and comparable immune recovery.
TSLP is an IL-7 like cytokine mainly produced by
epithelial cells in skin, lung, gut and thymus [32]. Due to
its role in priming of naïve CD4+ T cells towards a Th2
response, TSLP has been described to have an essential
role in the initiation of allergic diseases [33, 34]. Interest-
ingly, TSLP has a prominent role also in promoting
homeostatic polyclonal proliferation of CD4+ T cells and
in regulating Th17/regulatory T-cell balance [25, 35]. All
factors that are affected even in the early stages of HIV
infection [11, 36, 37]. With this in mind, we speculated
that TSLP would be less perturbed in PHI compared to
chronic HIV infection. No previous studies of plasma
TSLP in HIV infection exists. However, Fontenot and
colleagues described HIV-induced TSLP mRNA expres-
sion in human genital epithelial cells in early stages of
the infection [38]. We found higher plasma TSLP in in-
dividuals with primary HIV infection compared to both
chronic HIV infection and healthy controls. Interest-
ingly, individuals who initiated cART during primary
HIV infection maintained higher concentration of TSLP
compared to LP-AD and EP even after 24 months of
cART, suggesting that timing of initiation of cART has
important long-term effects on TSLP homeostasis.
However, TSLP was not associated with CD4+ T cell
recovery, and the impact of this finding remains unclear.
Interestingly, TSLP was a negative predictor for CD4+ T
cell recovery in HIV-infected individuals with a low CD4+
T cell count at the time of initiation of cART. We specu-
late that in individuals with impaired immune system in-
creased TSLP may be a response to low CD4+ T cell
counts rather than a cause of poor immune recovery.
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with PHI was associated with a lower proportion of RTE.
We speculate that loss of CD4+ T cells during primary HIV
infections leads to increased production of TSLP, but unfor-
tunately we do not have access to samples at the time of
seroconversion and therefore not data to support this
hypothesis. On the other hand, plasmaTSLP was not associ-
ated with a lower thymic output in any of the groups with
chronic HIV infection. However, the latter finding may be
due to the limited number of patients during the follow-up.
TSLP has been suggested to be involved in maintaining a
homeostatic polyclonal proliferation in the CD4+ T cell cen-
tral memory compartment in healthy individuals [24]. In
contrast, we found no correlation between TSLP plasma
levels and the proportion of central memory CD4+ T cells,
albeit a positive correlation between TSLP and the propor-
tion of effector memory cells was found in early presenters.
This discrepancy may be due to different responses in HIV-
infected and uninfected individuals.
The present study is mainly limited by the relatively small
number of individuals with primary HIV infection and low
number of patients with samples after 24 months of follow-
up. This may result in low level of power for analyses of as-
sociations at 24 months. Several comparisons are made, and
adjustments for multiple comparisons were not performed
which may lead to type I errors. A significance level of p <
0.05 was used, but a too restrict significance level may lead
to type II errors and failing of detecting a difference. Thus,
the results presented should be considered in the context of
both the number of comparisons and the a priori hypoth-
eses. Furthermore, the study is descriptive. Thus, conclu-
sions on causality cannot be made.
Conclusions
In conclusion, CD4+ T cell recovery and immune homeo-
stasis was comparable in individuals with primary HIV
infection and individuals with chronic HIV infection pre-
senting for care with CD4+ T cell counts <350 cells/μL.
Higher plasma TSLP was found in individuals with primary
HIV infection compared to both chronic HIV infection and
healthy controls. In primary HIV infection, TSLP was associ-
ated with lower thymic output, but TSLP was not associated
with CD4+ T cell recovery. In contrast, higher plasma TSLP
was associated with lower CD4+ T cell recovery in the LP-
nonAD. These findings indicate a possible role of TSLP in
immune homeostasis in HIV infection but do not support
TSLP to affect immune recovery in primary HIV infection.
Further studies in independent cohorts are warranted.
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